HUP9902618A2 - HIV-pozitív betegek kemoterápiájának irányítására szolgáló módszer humán HIV-törzsek fenotípusos gyógyszerérzékenységére alapozva - Google Patents

HIV-pozitív betegek kemoterápiájának irányítására szolgáló módszer humán HIV-törzsek fenotípusos gyógyszerérzékenységére alapozva

Info

Publication number
HUP9902618A2
HUP9902618A2 HU9902618A HUP9902618A HUP9902618A2 HU P9902618 A2 HUP9902618 A2 HU P9902618A2 HU 9902618 A HU9902618 A HU 9902618A HU P9902618 A HUP9902618 A HU P9902618A HU P9902618 A2 HUP9902618 A2 HU P9902618A2
Authority
HU
Hungary
Prior art keywords
hiv
chimeric
inhibitor
managing
chemotherapy
Prior art date
Application number
HU9902618A
Other languages
English (en)
Inventor
Marie-Pierre De Bethune
Kurt Hertogs
Rudi Pauwels
Original Assignee
Virco N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virco N.V. filed Critical Virco N.V.
Publication of HUP9902618A2 publication Critical patent/HUP9902618A2/hu
Publication of HUP9902618A3 publication Critical patent/HUP9902618A3/hu
Publication of HU226203B1 publication Critical patent/HU226203B1/hu

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

A találmány módszert ismertet HIV-pőzitív betegek HIV-kemőterápiájánakaz irányítására, amely a következő lépéseket tartalmazza: egy HIV-fertőzésre főgékőny sejtvőnalat egy szekvenciával, előnyösen egybetegből izőlált HIV-pől génjének RT és prőteázkódőló szekvenciájávalés egy HIV-DNS szerkezettel -, amelyből a szekvenciát törölték -transzfektálják, a transzfektált sejteket őlyan módőn tenyésztik, hőgyegy kiméravírűs törzs keletkezzék, meghatárőzzák a kiméravírűsőkfenőtí- pűsős érzékenységét egy HIV-pől gén által kódőlt enziminhibítőrral szemben, meghatárőznak erre egy értéket, összeállítanakegy adatsőrt, amely a kiméravírűs érzékenységértékeit és egy kiméravad típúsú HIV-törzs megfelelő értékét tartalmazza, megismétlik azérzékenységi vizsgálatőt legalább két tővábbi inhibítőrra vőnatkőzóan,miáltal összesen legalább hárőm adatból álló sőrt kapnak. Azadatsőrőkat kétdimenziós vagy hárőmdimenziós grafikűs főrmábanábrázőlják úgy, hőgy mindegyik adatsőrban a kiméra és vad típűsúérzékenység közötti különbség a kimératörzs rezisztenciájának vizűálismértékét adja meg a kérdéses inhibítőrral való kezeléshez. Az így mértrezisztenciák grafikűs ábrázőlása alapján kiválasztják az őptimálisinhibitőr(őka)t. A módszer az individűális HIV-fertőzött betegekrőlfenőtípűsős infőrmációt szőlgált, mégpedig nagy számban, gazdaságősanés győrsan. A módszer minden jelenleg használt kemőterápiásprőtőkőllra alkalmazható és valószínűleg űgyancsak alkalmazható lesz ajövőbeni kemőterápiás prőtőkőllőkra is. ŕ
HU9902618A 1996-01-26 1997-01-24 Method for determining of the chemotherapy of patients who are hiv positive based on the phenotypic drug sensitivity of human hiv strains HU226203B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96200175 1996-01-26
PCT/IB1997/000071 WO1997027480A1 (en) 1996-01-26 1997-01-24 Method of managing the chemotherapy of patients who are hiv positive based on the phenotypic drug sensitivity of human hiv strains

Publications (3)

Publication Number Publication Date
HUP9902618A2 true HUP9902618A2 (hu) 1999-12-28
HUP9902618A3 HUP9902618A3 (en) 2001-04-28
HU226203B1 HU226203B1 (en) 2008-06-30

Family

ID=8223611

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9902618A HU226203B1 (en) 1996-01-26 1997-01-24 Method for determining of the chemotherapy of patients who are hiv positive based on the phenotypic drug sensitivity of human hiv strains

Country Status (21)

Country Link
US (3) US6221578B1 (hu)
EP (1) EP0877937B1 (hu)
KR (1) KR100495690B1 (hu)
CN (2) CN1991365A (hu)
AT (1) ATE217971T1 (hu)
AU (1) AU717755B2 (hu)
BG (1) BG102710A (hu)
BR (1) BR9707204A (hu)
CZ (1) CZ292899B6 (hu)
DE (1) DE69712731T2 (hu)
ES (1) ES2177922T3 (hu)
HU (1) HU226203B1 (hu)
IL (1) IL125442A (hu)
IS (1) IS4799A (hu)
NO (1) NO321329B1 (hu)
NZ (1) NZ325912A (hu)
PL (1) PL186473B1 (hu)
SK (1) SK283878B6 (hu)
TR (1) TR199801443T2 (hu)
WO (1) WO1997027480A1 (hu)
ZA (1) ZA97669B (hu)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0656887T3 (da) 1992-08-25 1999-07-05 Searle & Co Hydroxyethylaminosulfonamider til anvendelse som inhibitorer af retrovirale proteaser
US20030220276A1 (en) * 1995-05-16 2003-11-27 Opendra Narayan HIV vaccine and method of use
US6242187B1 (en) 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US20070010471A1 (en) * 1997-05-02 2007-01-11 Opendra Narayan HIV DNA vaccine
JP2001512036A (ja) * 1997-07-30 2001-08-21 バイアラジック・インコーポレーテッド 抗ウイルス薬剤感受性および耐性を測定するための組成物および方法、並びに抗ウイルス薬剤をスクリーニングするための組成物および方法
MXPA00011623A (es) * 1998-05-26 2002-10-17 Virologic Inc Medios y metodos para verificar la terapia antirretroviral con inhibidor no nucleosidico de la transcriptasa inversa.
BR0011555A (pt) * 1999-05-28 2002-02-26 Virco Nv Perfis mutacionais em transcriptase reversa de hiv-1 correlacionada com resistência fenotìpica à droga
US6800437B1 (en) 1999-08-06 2004-10-05 Tibotec Bvba Method of monitoring a biological system by labeling with an apo metal binding protein
EP1109019A1 (en) * 1999-12-15 2001-06-20 BioStrands S.r.l. Method to evaluate the sensitivity of HIV variants to drugs able to inhibit the HIV protease
WO2001057245A2 (en) * 2000-02-04 2001-08-09 K.U.Leuven Research & Development Hiv-1 resistance assay
GB0009374D0 (en) * 2000-04-14 2000-05-31 Glaxo Group Ltd Phenotyping assay and reagents therefor
WO2001079540A2 (en) * 2000-04-18 2001-10-25 Virco Bvba Methods for measuring drug resistance
CA2406830C (en) * 2000-04-20 2012-10-02 Virco Bvba Method for mutation detection in hiv using pol sequencing
US6800463B1 (en) * 2000-04-20 2004-10-05 Virco Bvba Method for mutation detection in HIV-1 using pol sequencing
US6582901B2 (en) * 2000-04-26 2003-06-24 Bruce K. Patterson Cell specific anti-viral drug susceptibility test using tagged permissive target cells
US7058616B1 (en) 2000-06-08 2006-06-06 Virco Bvba Method and system for predicting resistance of a disease to a therapeutic agent using a neural network
WO2001096611A1 (en) * 2000-06-12 2001-12-20 Virologic, Inc. Means and methods for monitoring antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
US6582920B2 (en) * 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
WO2002033638A2 (en) 2000-10-20 2002-04-25 Virco Bvba Mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
AU1234402A (en) * 2000-10-20 2002-04-29 Virco Nv Establishment of biological cut-off values for predicting resistance to therapy
US7306901B2 (en) 2001-08-08 2007-12-11 Tibotec Pharmaceuticals, Ltd. Methods and means for assessing HIV envelope inhibitor therapy
US6958211B2 (en) * 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
ES2302860T3 (es) 2001-11-08 2008-08-01 Tibotec Pharmaceuticals Ltd. Ensayo de proteasas para la monitorizacion terapeutica de farmacos.
WO2004003817A1 (en) 2002-07-01 2004-01-08 Tibotec Pharmaceuticals Ltd. Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance
US7473524B2 (en) 2002-07-01 2009-01-06 Hilde Azijn Mutational profiles in HIV-1 protease correlated with phenotypic drug resistance
EP1728186A2 (en) 2004-03-02 2006-12-06 Virco Bvba Estimation of clinical cut-offs
WO2007065926A1 (en) 2005-12-07 2007-06-14 Tibotec Pharmaceuticals Ltd. Methods, plasmid vectors and primers for assessing hiv viral fitness
US20100009341A1 (en) * 2006-04-14 2010-01-14 Inky Paul Madeleine De Baere Methods and means for assessing hiv gag/protease inhibitor therapy
US20100173282A1 (en) 2007-05-25 2010-07-08 Tibotec Pharmaceuticals Ltd. Mutational profile in hiv-1 gag cleavage site correlated with phenotypic drug resistance
ES2546190T3 (es) * 2008-10-06 2015-09-21 Janssen Diagnostics Bvba Método para determinar mutaciones de resistencia a fármacos en cualquiera de las regiones de proteína no estructural NS3 a NS5B del virus de la hepatitis C (HCV) para los genotipos 1 a 6
WO2010130731A1 (en) * 2009-05-12 2010-11-18 Virco Bvba Hiv-1-c resistance monitoring
CN107085093B (zh) * 2017-03-24 2019-06-21 西藏诺迪康药业股份有限公司 重组人白细胞介素1受体拮抗剂滴眼液生物学活性的检测方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3875396A (en) * 1973-11-12 1975-04-01 Illuminite Corp Illuminated clipboard
US4675147A (en) * 1983-04-06 1987-06-23 Westinghouse Electic Corp. Generating an integrated graphic display of the safety status of a complex process plant
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
DK0406557T3 (da) 1989-05-25 2002-02-11 Univ Duke Multivalent repressor af genfunktion
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
JPH05148202A (ja) * 1991-04-10 1993-06-15 Tsumura & Co 新規な化合物およびその医薬としての用途
WO1993023574A1 (en) 1992-05-14 1993-11-25 Kozal Michael J Polymerase chain reaction assays for monitoring antiviral therapy
US5733720A (en) 1992-06-18 1998-03-31 Washington University Genetically engineered cell lines for detecting infectious herpesvirus and methods therefor
WO1994001584A1 (en) 1992-07-06 1994-01-20 President And Fellows Of Harvard College Methods and diagnostic kits for determining toxicity utilizing bacterial stress promoters fused to reporter genes
US5344846A (en) 1992-12-30 1994-09-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for inhibiting deoxyhypusine synthase and the growth of cells
US5591579A (en) 1993-12-21 1997-01-07 Washington University Indicator cell line for detecting RNA viruses and method therefor
US6063562A (en) 1994-09-16 2000-05-16 Sepracor, Inc. In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
AU6941196A (en) 1995-09-15 1997-04-17 Samir Chachoua Method for the identification and therapeutic use of disease-associated organisms, elements and forces
US5885806A (en) * 1995-11-28 1999-03-23 The Johns Hopkins University School Of Medicine Methods to prepare conditionally replicating viral vectors
AP9801360A0 (en) 1996-01-29 1998-12-31 Virologic Incorporated Compositions and methods ofr determining anti-viral drug susceptibility and resistance and anti-viral drug screening.
US5837464A (en) 1996-01-29 1998-11-17 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US5945276A (en) 1996-04-10 1999-08-31 Signal Pharmaceuticals, Inc. Reporter cell line system for detecting cytomegalovirus and identifying modulators of viral gene expression
US5939253A (en) 1996-04-26 1999-08-17 Diagnostic Hybrids, Inc. Compositions and methods for detecting viral infection
DE69824763T2 (de) 1997-04-07 2005-07-07 Bioimage A/S Verfahren zum Screenen von Substanzen die einen effekt auf intrazelluläre Translokation haben
US6365347B1 (en) 1997-04-11 2002-04-02 The Regents Of The University Of California Method for identifying disruptors of biological pathways using genetic selection
WO1998059074A1 (en) 1997-06-23 1998-12-30 Emory University Human immunodeficiency viruses causing aids in a nonhuman primate
US5976813A (en) 1997-12-12 1999-11-02 Abbott Laboratories Continuous format high throughput screening

Also Published As

Publication number Publication date
BR9707204A (pt) 1999-12-28
SK100298A3 (en) 1999-02-11
DE69712731T2 (de) 2003-02-06
NO983300L (no) 1998-09-25
US6221578B1 (en) 2001-04-24
NO983300D0 (no) 1998-07-16
WO1997027480A1 (en) 1997-07-31
IS4799A (is) 1998-07-20
ES2177922T3 (es) 2002-12-16
US20030152917A1 (en) 2003-08-14
HUP9902618A3 (en) 2001-04-28
IL125442A0 (en) 1999-03-12
DE69712731D1 (de) 2002-06-27
BG102710A (en) 1999-03-31
CN1991365A (zh) 2007-07-04
PL186473B1 (pl) 2004-01-30
US6528251B2 (en) 2003-03-04
TR199801443T2 (xx) 1998-10-21
EP0877937B1 (en) 2002-05-22
NZ325912A (en) 1999-01-28
NO321329B1 (no) 2006-04-24
HU226203B1 (en) 2008-06-30
CN1209875A (zh) 1999-03-03
ZA97669B (en) 1998-06-25
EP0877937A1 (en) 1998-11-18
KR19990082027A (ko) 1999-11-15
CZ292899B6 (cs) 2003-12-17
AU1316897A (en) 1997-08-20
PL328069A1 (en) 1999-01-04
US20020042679A1 (en) 2002-04-11
SK283878B6 (sk) 2004-04-06
CZ233598A3 (cs) 1999-06-16
IL125442A (en) 2002-03-10
AU717755B2 (en) 2000-03-30
KR100495690B1 (ko) 2005-11-08
ATE217971T1 (de) 2002-06-15

Similar Documents

Publication Publication Date Title
NZ325912A (en) Method of managing the chemotherapy of patients who are hiv positive based on the phenotypic drug sensitivity of human hiv strains
Hammer et al. Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells
Kong et al. Disruption of an antimycobacterial circuit between dendritic and helper T cells in human SPPL2a deficiency
Pion et al. HIV infection of human regulatory T cells downregulates Foxp3 expression by increasing DNMT3b levels and DNA methylation in the FOXP3 gene
Moens et al. Chromosome number of a small protist: accurate determination
Dong et al. Loss of methylation at the IFNG promoter and CNS‐1 is associated with the development of functional IFN‐γ memory in human CD 4+ T lymphocytes
Bsat et al. Differential pathogenic Th17 profile in mesenteric lymph nodes of Crohn's disease and ulcerative colitis patients
Mostowy et al. The role of recombination for the coevolutionary dynamics of HIV and the immune response
Elsner et al. Absence of cGAS-mediated type I IFN responses in HIV-1–infected T cells
Thyagarajan et al. Elevated homologous recombination activity in fanconi anemia fibroblasts
Chinen et al. Advances in basic and clinical immunology in 2014
Riou et al. Severe symptomatic primary human cytomegalovirus infection despite effective innate and adaptive immune responses
Sun et al. A transcriptional signature of IL-2 expanded natural killer cells predicts more favorable prognosis in bladder cancer
Pillay et al. Somatic reversion of pathogenic DOCK8 variants alters lymphocyte differentiation and function to effectively cure DOCK8 deficiency
van den Ham et al. From the two-dimensional Th1 and Th2 phenotypes to high-dimensional models for gene regulation
Baron et al. Impact of anti PD-1 immunotherapy on HIV reservoir and anti-viral immune responses in people living with HIV and cancer
Roy Chowdhury et al. NK-like CD8+ γδ T cells are expanded in persistent Mycobacterium tuberculosis infection
GR3017271T3 (en) Double-stranded RNA correction of RNase L deficiency.
Fisher et al. Unequal distribution of genetically-intact HIV-1 proviruses in cells expressing the immune checkpoint markers PD-1 and/or CTLA-4
Chen et al. Methods taught in dental schools for determining the posterior palatal seal region.
Edwards et al. Palmitoylation and p8-mediated human T-cell leukemia virus type 1 transmission
Picton et al. Reduced CCR5 Expression and Immune Quiescence in Black South African HIV-1 Controllers
Salgado et al. Control of HIV-1 pathogenesis in viremic nonprogressors is independent of Gag-specific cytotoxic T lymphocyte responses
Phillips Caregiving and ethnicity
He et al. Two amino acid mutation disrupts RORγt function in Th17 differentiation but not thymocyte development

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees